Kim, Dae Won
Tan, Elaine
Zhou, Jun-Min
Schell, Michael J.
Martinez, Maria
Yu, James
Carballido, Estrella
Mehta, Rutika
Strosberg, Jonathan
Imanirad, Iman
Kim, Richard D.
Funding for this research was provided by:
Janssen Pharmaceuticals
Article History
Received: 11 December 2020
Revised: 9 March 2021
Accepted: 19 March 2021
First Online: 7 April 2021
Ethics approval and consent to participate
: The protocol and informed consent forms were approved by the Institutional Review Boards at Moffitt Cancer Center (IRB# 00000790). Informed consent was obtained from all subjects prior to participating in the study. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
: Not applicable.
: All authors had access to the data published in this paper. The anonymised dataset may be available from the corresponding author on reasonable request.
: Rutika Mehta reported advisory/consulting for Taiho Oncology, Bristol Myers Squibb and Eli Lilly. Jonathan Strosberg reported consulting for Novartis. Richard Kim received an honorarium from Eli Lilly, Bristol Myers Squibb and Bayer. The remaining authors declare no competing interests.
: This work was supported by Janssen Oncology and Merck.